← Leaderboards

Michael I Nishimura

University Of Chicago

Google Scholar ↗PubMed ↗ORCID ↗

$19,220,002

Attributed

$22,202,432

Total exposure

19

Grants

15

Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $7M · FY2005–25

$10M$7.5M$5M$2.5M$0

'05

'06

'07

'08

'09

'10

'11

'12

'13

'14

'15

'16

'17

'18

'19

'20

'21

'22

'23

'24

'25

Funding mix

By agency

NIH$37,571,507 · 20

By mechanism

P01$26,712,802 · 13

R01$10,149,355 · 5

R21$709,350 · 2

Top collaborators

Most similar at University Of Chicago

Same institution · by research overlap

Jeffrey A Bluestone$76,504,040
Erin June Adams$25,653,012
Hans Schreiber$12,391,832

Others in their field

Top investigators on “T-Lymphocyte”

Barton F Haynes · Duke University$296,833,570
Lawrence Corey · Fred Hutchinson Cancer Center$270,341,865
Dan H. Barouch · Fred Hutchinson Cancer Center$117,305,894
Margaret Juliana McElrath · Fred Hutchinson Cancer Center$107,651,960
Alessandro Sette · La Jolla Institute For Immunology$75,756,097
Rama Rao Amara · Emory University$69,530,112

Research focus

T-LymphocyteClinical TrialsTumorMelanomaGene-ModifiedResponseAntigensIn VivoAffinitySourceCellsEngineeringAdoptive ImmunotherapyIn VitroMalignant NeoplasmsCd8b1 GeneNeoplastic CellReportingBaseGenesMonophenol MonooxygenaseHla-A2 AntigenProgramsAutologous

Grant awards (66)

Time to ATTAC: Adoptive Transfer of T cells Against gp100+ Cells to treat LAM$593,023

R01 · FY2025 · HL

Time to ATTAC: Adoptive Transfer of T cells Against gp100+ Cells to treat LAM$584,415

R01 · FY2024 · HL

Time to ATTAC: Adoptive Transfer of T cells Against gp100+ Cells to treat LAM$605,116

R01 · FY2023 · HL

Building better T cell receptors for targeted immunotherapy$686,715

R01 · FY2021 · AI

Building better T cell receptors for targeted immunotherapy$755,580

R01 · FY2020 · AI

Building better T cell receptors for targeted immunotherapy$828,987

R01 · FY2019 · AI

Building better T cell receptors for targeted immunotherapy$720,706

R01 · FY2018 · AI

: Building better T cell receptors for targeted immunotherapy$56,115

R01 · FY2018 · AI

Building better T cell receptors for targeted immunotherapy$772,935

R01 · FY2017 · AI

TCR Gene Modified T Cells for Adoptive Immunotherapy$3,406,082

P01 · FY2015 · CA · contact PI

CELL THERAPY CORE$1,080,576

P01 · FY2015 · CA · contact PI

CLINICAL TRIALS USING TCR TRANSDUCED T CELL FOR ADOPTIVE IMMUNOTHERAPY$768,601

P01 · FY2015 · CA · contact PI

IMPACT OF AICD ON TCR TRANSDUCED T CELLS FOR ADOPTIVE IMMUNOTHERAPY$334,756

P01 · FY2015 · CA · contact PI

MOUSE CORE$246,637

P01 · FY2015 · CA · contact PI

IMPACT OF IMMUNE SUPPRESSION ON TCR-TRANSDUCED T CELLS FOR ADOPTIVE$242,781

P01 · FY2015 · CA · contact PI

TCR TRANSDUCED CDB T CELLS FOR ADOPTIVE IMMUNOTHERAPY$229,519

P01 · FY2015 · CA · contact PI

TCR TRANSDUCED CD4 T CELLS FOR ADOPTIVE IMMUNOTHERAPY$216,049

P01 · FY2015 · CA · contact PI

TCR/DAP10 chimera as a means to attaining persistent anti-tumor T cell responses$197,055

R21 · FY2015 · CA

BIOSTATISTICS CORE$158,729

P01 · FY2015 · CA · contact PI

ADMINISTRATIVE CORE$128,434

P01 · FY2015 · CA · contact PI

TCR Gene Modified T Cells for Adoptive Immunotherapy$3,295,681

P01 · FY2014 · CA · contact PI

CELL THERAPY CORE$1,019,060

P01 · FY2014 · CA · contact PI

CLINICAL TRIALS USING TCR TRANSDUCED T CELL FOR ADOPTIVE IMMUNOTHERAPY$737,794

P01 · FY2014 · CA · contact PI

IMPACT OF AICD ON TCR TRANSDUCED T CELLS FOR ADOPTIVE IMMUNOTHERAPY$313,532

P01 · FY2014 · CA · contact PI

TCR TRANSDUCED CDB T CELLS FOR ADOPTIVE IMMUNOTHERAPY$304,484

P01 · FY2014 · CA · contact PI

MOUSE CORE$229,727

P01 · FY2014 · CA · contact PI

IMPACT OF IMMUNE SUPPRESSION ON TCR-TRANSDUCED T CELLS FOR ADOPTIVE$226,064

P01 · FY2014 · CA · contact PI

TCR TRANSDUCED CD4 T CELLS FOR ADOPTIVE IMMUNOTHERAPY$201,200

P01 · FY2014 · CA · contact PI

TCR/DAP10 chimera as a means to attaining persistent anti-tumor T cell responses$164,213

R21 · FY2014 · CA

BIOSTATISTICS CORE$146,128

P01 · FY2014 · CA · contact PI

ADMINISTRATIVE CORE$117,692

P01 · FY2014 · CA · contact PI

TCR Gene Modified T Cells for Adoptive Immunotherapy$3,141,645

P01 · FY2013 · CA · contact PI

CELL THERAPY CORE$1,010,803

P01 · FY2013 · CA · contact PI

CLINICAL TRIALS USING TCR TRANSDUCED T CELL FOR ADOPTIVE IMMUNOTHERAPY$735,043

P01 · FY2013 · CA · contact PI

IMPACT OF AICD ON TCR TRANSDUCED T CELLS FOR ADOPTIVE IMMUNOTHERAPY$297,164

P01 · FY2013 · CA · contact PI

TCR TRANSDUCED CDB T CELLS FOR ADOPTIVE IMMUNOTHERAPY$285,652

P01 · FY2013 · CA · contact PI

IMPACT OF IMMUNE SUPPRESSION ON TCR-TRANSDUCED T CELLS FOR ADOPTIVE$205,254

P01 · FY2013 · CA · contact PI

MOUSE CORE$204,887

P01 · FY2013 · CA · contact PI

TCR TRANSDUCED CD4 T CELLS FOR ADOPTIVE IMMUNOTHERAPY$181,225

P01 · FY2013 · CA · contact PI

BIOSTATISTICS CORE$124,986

P01 · FY2013 · CA · contact PI

ADMINISTRATIVE CORE$96,631

P01 · FY2013 · CA · contact PI

TCR Gene Modified T Cells for Adoptive Immunotherapy$3,493,020

P01 · FY2012 · CA · contact PI

Cell Therapy Core$1,041,313

P01 · FY2012 · CA · contact PI

TCR Transduced CD4+ T Cells for Adoptive Immunotherapy$269,531

P01 · FY2012 · CA · contact PI

Administrative Core$189,475

P01 · FY2012 · CA · contact PI

TCR Gene Modified T Cells for Adoptive Immunotherapy$2,032,647

P01 · FY2011 · CA · contact PI

TCR Affinity and Therapeutic Efficacy of T Cells$211,935

R01 · FY2011 · CA · contact PI

TCR Engineering of Quiescent Primary Human T Cells$126,695

R21 · FY2011 · CA · contact PI

TCR Affinity and Therapeutic Efficacy of T Cells$72,521

R01 · FY2011 · CA · contact PI

TCR Engineering of Quiescent Primary Human T Cells$28,899

R21 · FY2011 · CA · contact PI

TCR Affinity and Therapeutic Efficacy of T Cells$293,100

R01 · FY2010 · CA · contact PI

TCR Engineering of Quiescent Primary Human T Cells$192,488

R21 · FY2010 · CA · contact PI

TCR Affinity and Therapeutic Efficacy of T Cells$299,698

R01 · FY2009 · CA · contact PI

TCR Affinity and Therapeutic Efficacy of T Cells$292,953

R01 · FY2009 · CA · contact PI

TCR Affinity and Therapeutic Efficacy of T Cells$122,881

R01 · FY2009 · CA · contact PI

TCR Affinity and Therapeutic Efficacy of T Cells$292,809

R01 · FY2008 · CA · contact PI

TCR Affinity and Therapeutic Efficacy of T Cells$303,994

R01 · FY2007 · CA · contact PI

Animal Model for Her-2/neu Specific TCR Gene Transfer$263,355

R01 · FY2007 · CA · contact PI

Animal Model for Her-2/neu Specific TCR Gene Transfer$280,412

R01 · FY2006 · CA · contact PI

Animal Model for Her-2/neu Specific TCR Gene Transfer$280,188

R01 · FY2005 · CA

Tumor Recognition by TCR Transduced CD4+ and CD8+T Cells$313,325

R01 · FY2004 · CA

Animal Model for Her-2/neu Specific TCR Gene Transfer$281,910

R01 · FY2004 · CA

Tumor Recognition by TCR Transduced CD4+ and CD8+T Cells$313,325

R01 · FY2003 · CA

Animal Model for Her-2/neu Specific TCR Gene Transfer$296,707

R01 · FY2003 · CA

Tumor Recognition by TCR Transduced CD4+ and CD8+T Cells$313,325

R01 · FY2002 · CA

Tumor Recognition by TCR Transduced CD4+ and CD8+T Cells$313,325

R01 · FY2001 · CA